7 results on '"Boers, Maarten"'
Search Results
2. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
- Author
-
Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, and Boers M
- Subjects
- Age Factors, Aged, Antirheumatic Agents adverse effects, Antirheumatic Agents economics, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid economics, Arthritis, Rheumatoid physiopathology, Clinical Trials, Phase IV as Topic, Cost-Benefit Analysis, Double-Blind Method, Drug Costs, Drug Therapy, Combination, Europe, Female, Glucocorticoids adverse effects, Glucocorticoids economics, Humans, Male, Medication Adherence, Multicenter Studies as Topic, Pragmatic Clinical Trials as Topic, Prednisolone adverse effects, Prednisolone economics, Risk Factors, Time Factors, Treatment Outcome, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Glucocorticoids administration & dosage, Prednisolone administration & dosage
- Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 1% of the world population. It has major impact on patients through disability and associated comorbidities. Current treatment strategies have considerably improved the prognosis, but recent innovations (especially biologic drugs and the new class of so-called "JAK/STAT inhibitors") have important safety issues and are very costly. Glucocorticoids (GCs) are highly effective in RA, and could reduce the need for expensive treatment with biologic agents. However, despite more than 65 years of clinical experience, there is a lack of studies large enough to adequately document the benefit/harm balance. The result is inappropriate treatment strategies, i.e. both under-use and over-use of GCs, and consequently suboptimal treatment of RA., Methods: The GLORIA study is a pragmatic multicentre, 2-year, randomised, double-blind, clinical trial to assess the safety and effectiveness of a daily dose of 5 mg prednisolone or matching placebo added to standard of care in elderly patients with RA. Eligible participants are diagnosed with RA, have inadequate disease control (disease activity score, DAS28 ≥ 2.6), and are ≥ 65 years. The primary outcome measures are the time-averaged mean value of the DAS28 and the occurrence of serious adverse events or adverse events of special interest. During the trial, change in antirheumatic therapy is permitted as clinically indicated, except for GCs. Cost-effectiveness and cost-utility are secondary outcomes. The main challenge is the interpretation of the trial result with two primary endpoints and the pragmatic trial design that allows co-interventions. Another challenge is the definition of safety and the relative lack of power to detect differences between treatment groups. We have chosen to define safety as the number of patients experiencing at least one serious adverse event. We also specify a decision tree to guide our conclusion on the balance of benefit and harm, and our methodology to combat potential confounding caused by co-interventions., Discussion: Pragmatic trials minimise impact on daily practice and maximise clinical relevance of the results, but analysis and interpretation of the results is challenging. We expect that the results of this trial are of importance for all rheumatologists who treat elderly patients with RA., Trial Registration: ClinicalTrials.gov, NCT02585258 . Registered on 20 October 2015.
- Published
- 2018
- Full Text
- View/download PDF
3. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
- Author
-
Hartman, Linda, Silva, José A P da, Buttgereit, Frank, Cutolo, Maurizio, Opris-Belinski, Daniela, Szekanecz, Zoltan, Masaryk, Pavol, Voshaar, Marieke J H, Heymans, Martijn W, Lems, Willem F, Heijde, Désirée M F M van der, and Boers, Maarten
- Subjects
DISEASE progression ,GLUCOCORTICOIDS ,PREDNISOLONE ,PATIENT selection ,RESEARCH methodology ,REGRESSION analysis ,RHEUMATOID arthritis ,RESEARCH funding ,PREDICTION models ,LOGISTIC regression analysis ,COMORBIDITY ,OLD age - Abstract
Objective To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo. Methods In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients ≥65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were developed from the dataset in a stepwise procedure based on prior knowledge. The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of low-dose prednisolone. In each set, two models focused on harm [the occurrence of one or more adverse events of special interest (AESIs) and the number of AESIs per year) and two on benefit (early clinical response/disease activity and a lack of joint damage progression). Linear and logistic multivariable regression methods with backward selection were used to develop the models. The final models were assessed and internally validated with bootstrapping techniques. Results A few variables were slightly predictive for one of the outcomes in the models, but none were of immediate clinical value. The quality of the prediction models was sufficient and the performance was low to moderate (explained variance 12–15%, area under the curve 0.67–0.69). Conclusion Baseline factors are not helpful in selecting elderly RA patients for treatment with low-dose prednisolone given their low power to predict the chance of benefit or harm. Trial registration https://clinicaltrials.gov ; NCT02585258. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
- Author
-
Boers, Maarten, Hartman, Linda, Opris-Belinski, Daniela, Bos, Reinhard, Kok, Marc R., Da Silva, Jose A. P., Griep, Eduard N., Klaasen, Ruth, Allaart, Cornelia F., Baudoin, Paul, Raterman, Hennie G., Szekanecz, Zoltan, Buttgereit, Frank, Masaryk, Pavol, Klausch, L. Thomas, Paolino, Sabrina, Schilder, Annemarie M., Lems, Willem F., Cutolo, Maurizio, and Da Silva, Jose Ap
- Subjects
GLUCOCORTICOIDS ,RESEARCH ,PREDNISOLONE ,COMBINATION drug therapy ,RESEARCH methodology ,EVALUATION research ,METHOTREXATE ,ANTIRHEUMATIC agents ,TREATMENT effectiveness ,COMPARATIVE studies ,RANDOMIZED controlled trials ,RHEUMATOID arthritis ,BLIND experiment - Abstract
Background: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear.Methods: The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and those causing study discontinuation. Longitudinal models analysed the data, with one-sided testing and 95% confidence limits (95% CL).Results: We randomised 451 patients with established RA and mean 2.1 comorbidities, age 72, disease duration 11 years and DAS28 4.5. 79% were on disease-modifying treatment, including 14% on biologics. 63% prednisolone versus 61% placebo patients completed the trial. Discontinuations were for AE (both, 14%), active disease (3 vs 4%) and for other (including covid pandemic-related disease) reasons (19 vs 21%); mean time in study was 19 months. Disease activity was 0.37 points lower on prednisolone (95% CL 0.23, p<0.0001); joint damage progression was 1.7 points lower (95% CL 0.7, p=0.003). 60% versus 49% of patients experienced the harm outcome, adjusted relative risk 1.24 (95% CL 1.04, p=0.02), with the largest contrast in (mostly non-severe) infections. Other GC-specific events were rare.Conclusion: Add-on low-dose prednisolone has beneficial long-term effects in senior patients with established RA, with a trade-off of 24% increase in patients with mostly non-severe AE; this suggests a favourable balance of benefit and harm.Trial Registration Number: NCT02585258. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis.
- Author
-
Kerstens, Floor, Spijkers, Karin, Wolthuis, David, Boers, Maarten, Herwaarden, Noortje van, and Cate, David ten
- Subjects
GLUCOCORTICOIDS ,PREDNISOLONE ,GENERIC drug substitution ,DEXAMETHASONE ,BIOAVAILABILITY ,GENETIC variation ,ISOENZYMES ,RHEUMATOID arthritis ,PHARMACODYNAMICS - Abstract
The article reports a response after switching from prednisole to dexamethasone in three D2T-RA patients with active disease despite prednisolone. Topics discussed include possible mechanisms why response to different glucocorticoids (GCs) may vary, pharmacodynamic differences between GCs, and characteristics of 3 ACPA-positive patients switched from prednisolone to dexamethasone.
- Published
- 2024
- Full Text
- View/download PDF
6. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.
- Author
-
Konijn, Nicole P. C., van Tuyl, Lilian H. D., Boers, Maarten, van de Ven, Peter M., den Uyl, Debby, ter Wee, Marieke M., Kerstens, Pit, Voskuyl, Alexandre E., van Schaardenburg, Dirkjan, Lems, Willem F., and Nurmohamed, Michael T.
- Subjects
ACADEMIC medical centers ,ADIPOSE tissues ,BODY composition ,COMBINATION drug therapy ,LONGITUDINAL method ,QUESTIONNAIRES ,RESEARCH funding ,RHEUMATOID arthritis ,STATISTICAL sampling ,SECONDARY analysis ,DATA analysis software ,DESCRIPTIVE statistics ,PREDNISOLONE ,PHOTON absorptiometry ,DYADIC Adjustment Scale - Abstract
Objective. To investigate the effect of two different high-dose, step-down prednisolone regimens on body composition in early RA patients after 26 weeks of treatment. Methods. Prednisolone-naive patients with recent-onset RA (n = 108) were randomized to either COBRA (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks; MTX and SSZ) or COBRA-light therapy (prednisolone 30 mg/day, tapered to 7.5 mg/day in 8 weeks and MTX). Body composition was assessed at baseline (before or soon after start of treatment) and after 26 weeks with DXA, and recorded as total body mass (TBM), total fat mass (FM), total lean mass (LM) and trunk/peripheral fat ratio. Log-ratio analyses assessed the proportional distribution of TBM (between LM, FM and bone mass) and FM (between trunk, extremities and head). The subgroup of patients with a DXA before start of treatment (n = 38) was analysed separately. Results. In the subgroup of patients with a DXA before start of treatment, TBM increased by 1.6 kg (P < 0.001) and total FM by 1.3 kg (P < 0.001). The trunk/peripheral fat ratio and the proportional distribution of TBM and FM remained stable over time. There were no differences between the treatment groups. Similar results were obtained in the study population as a whole. Conclusion. Both high-dose, step-down prednisolone regimens caused increases in TBM, mainly caused by an increase in FM, but we found no fat redistribution from peripheral to central tissues. This absence in fat redistribution contradicts the widely held assumption of rapid adverse effects of prednisolone on body composition in RA. Trial registration: ISRCTNregistry, http://www.isrctn.com, ISRCTN55552928 [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. COBRA Combination Therapy in Rheumatoid Arthritis: Implementation and Beyond
- Author
-
van Tuyl, H.D., Dijkmans, B.A.C., Boers, M., Lems, W.F., Voskuijl, A.E., Dijkmans, Ben, Boers, Maarten, Lems, Willem, Voskuyl, Alexandre, Rheumatology, and CCA - Innovative therapy
- Subjects
musculoskeletal diseases ,combination therapy ,prednisolone ,remission ,COBRA therapy ,rheumatoid arthritis ,glucocorticoids - Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.